We have studied the effect of acute and sub-chronic treatments of a formulation of a methanolic extract of hypericum perforatum (HP, also known as St John’s wort) on plasma hormones and brain neurotransmitters in healthy human volunteers and rats. Also studied were the effects of equivalent acute doses of two constituents of HP (with respect to LI 160 extract), hypericin and hyperforin in rats. In acute treatment studies in normal volunteers subjects received 9 tablets of the finished product Jarsin®300 and placebo in the pilot study (unblinded) and in the main study (a double blind, balanced order, cross-over design). Results in normal volunteer studies show that HP caused significant increases of salivary cortisol and plasma growth hormone (GH) whereas it decreased plasma prolactin versus placebo. Plasma hormone levels were associated with a rise in plasma hyperforin but not with hypericin, however no significant correlation was found. In the animal studies, acute treatment with LI 160, hyperforin and hypericin all caused significant increases in plasma corticosterone. This was associated with significant increases in brain cortical tissue 5-HT content. The corticosterone responses were attenuated by the 5-HT2 receptor antagonist, ketanserin but not by the 5-HT1A antagonist, WAY-100 635. This suggests that the corticosterone responses may be mediated via a 5-HT2 mechanism of action. When sub-chronic and acute treatment using two different doses of LI 160 were compared, plasma corticosterone level were significantly decreased. Thus suggesting a down-regulation or desensitisation of post-synaptic 5-HT2 receptors. Plasma prolactin was significantly reduced by acute treatment with LI 160 and hyperforin treatment but not by hypericin. This was associated with a concomitant rise in brain cortical tissue DA. Both LI 160 and hyperforin treatments decreased the plasma prolactin responses to the DA antagonist, haloperidol, suggesting that this may be associated with a DA-mediated mechanisn of action. When acute and sub-chronic treatments were compared, plasma prolactin responses were increased in the sub-chronically treated animals. The studies when taken together suggest that the LI 160 extract may effect plasma hormonal changes via both 5-HT and DA-mediated mechanisms but do not involve noradrenaline (NA). The data also suggests that hyperforin may be more important than hypericin for effecting these changes following acute treatment. Further studies investigating both acute and sub-chronic effects of these compounds are necessary.
References
-
1
Arnett C D, Wolf A P, Shine H.
Improved delineation of human dopamine receptors using 18F-N-methylspiroperidol and PET.
J Nucl Med.
1986;
27
1878-1886
-
2
Ascher J A, Cole J A, Colin J N, Feighner J P, Ferris R M, Fiberger H C, Golden R N, Martin P, Potter W L, Richelson E, Sulser F.
A review of its mechanism of antidepressant activity.
J Clin Psychiat.
1995;
56
((9))
395-401
-
3
Agnis G M, Sanderson W C, Van Praag H M.
Cortisol response to intramuscular desipramine in patients with major depression and normal control subjects: a Replication study.
Psychiatry-Research.
1992;
44
(3)
237-250
-
4
Brockmoller J, Reum T, Bauer S, Kerb R, Hubner W D, Roots I.
Hypericin and pseudohypericin pharmacokinetics and effects on photosensitivity in humans.
Pharmcopsychiat.
1997;
30
(suppl)
94-101
-
5 Burns T G, Brown G M. The effects of acute and chronic desipramine treatment on pineal and serum melatonin and N-acetylserotonin. In: The Pineal gland. Ed. Brown GM and Wainwright SD Pergamon Press 1985: 25-30
-
6 Butterweck V, Nahrstedt A, Winterhoff H. Effects of hypericum perforatum extract and isolated constituents on neurotransmitter concentrations and endocrine parameters. Ann Congress of the Soc Of Med Plant Res 1998:
-
7
Calapai G, Crupi A, Firenzuoli F Costantino G, Inferrera G, Campo G M, Caputi A P.
Effects of hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline, dopamine in the cortex, diencephalon and brain stem of rats.
J Pharm Pharmacol.
1999;
51
723-728
-
8
Chi J, Odontiadis J, Franklin M.
Simultaneous determination of catecholamines in rat brain tissue by high performance liquid chromatography.
J Chromatography B.
1999;
731
361-367
-
9
Daffner-Bugia G, Laakman G, Voderholzer U, Haag C, Baghai T, Kolmsee S, Schroeder U, Munz T.
The neuroendocrine effects of venlafaxine in healthy subjects.
Human Psychophgarmacology.
1996;
11
((1))
1-9
-
10
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E.
Effect of acute administration of hypericum-CO2 extract on dopamine and serotonin release in the rat central nervous system.
Pharmacopsychiat.
2000;
33
((1))
14-18
-
11
Duncan G E, Knapp J D, Carson S W, Breese G R.
Differential effects of chronic antidepressant treatment on swim stress and fluoxetine-induced secretion of corticosterone and progesterone.
J Pharmacol and Exp Ther.
1998;
285
((2))
579-587
-
12
Ernst E.
Second thoughts about safety of St John’s wort.
Lancet.
1999;
354
((9195))
2014
-
13
Franklin M, McGavin C, Reed A, Cowen P J.
Effect of hypericum perforatum on salivary cortisol in healthy male volunteers.
J Psychopharmacol.
1998;
30
((suppl))
A16
-
14
Franklin M, Chi J, McGavin C, Hockney R, Reed A, Campling G, Whale R WR, Cowen P J.
Neuroendocrine evidence for dopaminergic actions of hypericum extract.
Biol psych.
1999;
46
581-584
-
15 Franklin M, Chi J, Mannel M, Cowen P J. Acute effects of LI160 (extract of Hypericum perforatum, St John's wort) and two of its constituents on neuroendocrine responses in the rat. J Psychopharmacology 2000
-
16
Harrer G, Schmidt U, Kuhn U, Biller A.
Comparison of equivalence between St John’s wort extract LoHyp-57 and fluoxetine.
Arzneimittel Forschung.
1999;
49
289-296
-
17
Hurt R D, Sachs D PL, Glover E D, Offord K P, Johnston J A, Lowell C D.
A comparison of sustained-release bupropion and placebo for smoking cessation.
The New England J of Med.
1997;
337
1195-1202
-
18
Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I.
pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort.
Clinical Pharmacology and Therapeutics.
1999;
66
338-45
-
19
Kaehler S T, Sinner C, Chatterjee S S, Philippu A.
Hyperforinenhances serotonin and glutamate in the rat locus ceoruleus.
Neuroscience letters.
1999;
262
199-202
-
20
Lantz M S, Buchalter E, Giambanco V.
St John’s wort and antidepressant drug interactions in the elderly.
J Geriatr Psychiatry Neurol.
1999;
12
7-10
-
21
Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D.
St John’s wort for depression an overview and meta-analysis of randomised clinical trials.
BMJ.
1996;
313
253-258
-
22
Maurer A, Johne A, Bauer S.
Interaction of St John’s wort extract with phenprocoumon.
Eur J Clin Pharmacol.
1999;
47
687-692
-
23
Muller W E, Rolli M, Schaffer C, Hafner U.
Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.
Pharmacopsychiat.
1997;
30(suppl)
102-107
-
24
Muller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C.
Hyperforin represents the neurotransmitter reuptake inhibiting constiuent of hypericum extract.
Pharmacopsychiat.
1998;
31
(Suppl1)
16-21
-
25
Nathan P J.
The experimental and clinical pharmacology of St Johns wort (Hypericum perforatum L.).
Molecular Psychiatry.
1999;
4
333-338
-
26
Nahrstedt A, Butterweck V.
Biologically active and other chemical constituents of the herb Hypericuperforatum.
Pharmacopsyciatry.
1997;
30
(Suppl2)
129-134
-
27
Nebel A, Schneider B J, Baker RK; Kroll D J.
Potential metabolic interaction between St Johns wort and theophyline.
Ann Pharmacother.
1999;
33
502
-
28
Philipp M, Kohnen R, Hiller K O.
Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.
BMJ.
1999;
319
1534-1539
-
29
Potter W L.
Bipolar depression: specific treatments.
J Clin Psychiat.
1998;
59
(Suppl18)
30-38
-
30
Rapp D K, Van de Kar L D.
Selective serotonin re-uptake inhibotors and neuroendocrine function.
Life Sciences.
1999;
65
((12))
1217-1235
-
31
Rolli M, Schafer C, Muller W E.
Effect of Hypericum extract (LI 160) on neurotransmitter receptor binding and synaptosomal uptake systems.
Pharmacopsychiatry.
1995;
28
207
-
32
Schüle C, Baghai T, Ferrera A, Laakmann G.
Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers.
Pharmacopsychiatry.
2001;
34
(suppl)
127-133
-
33
Skene D J, Bojowski C J, Arendt J.
Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.
Brit J Clin Pharmacol.
1994;
37
((2))
181-186
-
34
Teufel-Mayer R, Gleitz J.
Effects of log-term administration of hypericum extracts on the affinity and density of the central 5-HT1 A and 5-HT2 receptors.
Pharmacopsychiat.
1997;
30
(Suppl2)
113-116
-
35
Tuomisto J, Mannisto P.
Neurotransmitter regulation of pituitary hormones.
Pharmacol Exp Ther.
1985;
37
((3))
249-311
-
36
Volz H P.
Hypericum: an overview of published therapeutic trials.
Pharmacopsychiat.
1997;
30
((2))
72-76
-
37
Wheatley D.
LI 160, an extract of St John’s wort, versus amitryptiline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial.
Pharmacopsychiat.
1997;
30
(suppl)
77-80
-
38
Yatham L N, Steiner M.
Neuroendocrine probes of serotonergic function: a critical review.
Life Sciences.
1993;
53
((6))
447-463
-
39
Yu P H.
Effect of Hypericum perforatum extract on serotonin turnover in the mouse brain.
Pharmacopsychiat.
2001;
33
60-65
Dr. Mike Franklin
University of Oxford Department of Psychiatry
Warneford Hospital
Headington
Oxford OX 3, 7JX
UK
